Related Experiment Video

Updated: May 2, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K

MKL1-184C>T gene polymorphism is associated with coronary artery disease in the Chinese Han population

Y Xu1, B Li2, Y-Z Bao3

  • 1Department of Cardiology, People's Hospital of Henan Province, Zhengzhou, China yuxucn@126.com.

Genetics and Molecular Research : GMR
|March 12, 2014
PubMed

Insights

Genetic variations in the MKL1 gene are linked to coronary artery disease (CAD) susceptibility in the Chinese Han population. The MKL1 -184 T allele is associated with increased CAD risk and disease severity.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Population Genetics

Background:

  • Coronary artery disease (CAD) is a leading cause of mortality worldwide.
  • Identifying genetic factors contributing to CAD susceptibility is crucial for prevention and treatment.
  • The role of specific gene polymorphisms, such as those in the MKL1 gene, in CAD risk requires further investigation.

Purpose of the Study:

  • To investigate the association between MKL1 gene polymorphisms and the risk of coronary artery disease (CAD) in the Chinese Han population.
  • To determine if the MKL1 -184C>T polymorphism is a susceptibility factor for CAD.
  • To explore the correlation between MKL1 gene variants and the severity of coronary artery stenosis.

Main Methods:

  • A case-control study was conducted with 476 CAD patients and 325 non-CAD controls from the Chinese Han population.
  • Single nucleotide polymorphisms (SNPs) in the MKL1 gene were genotyped using a TaqMan SNP genotyping assay.
  • Logistic regression models were employed to analyze the association between MKL1 genotypes and CAD risk, adjusting for established risk factors.

Main Results:

  • The MKL1 -184C>T polymorphism was in Hardy-Weinberg equilibrium in both groups.
  • The frequency of the MKL1 T allele was significantly higher in CAD patients (38.6%) compared to controls (30.8%).
  • Carriers of CT or TT genotypes exhibited a significantly increased risk of CAD (OR = 1.780, 95% CI = 1.311-2.418).
  • The -184 T allele was associated with an increased risk of three-vessel disease (3VD) (OR = 1.614, 95% CI = 1.259-2.07).
  • Homozygosity for the T allele correlated with more severe coronary artery stenosis.

Conclusions:

  • The MKL1 -184C>T polymorphism is a significant genetic susceptibility factor for coronary artery disease in the Han Chinese population of Henan Province.
  • The presence of at least one T allele at the MKL1 -184 locus increases CAD risk.
  • The MKL1 -184 T allele is associated with both increased CAD risk and greater severity of coronary artery stenosis.

More Related Videos

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

12.7K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.6K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121